GoodRx Holdings, Inc. (GDRX) surged 37.00 percent to $5.11, up $1.38 on Monday, after announcing a collaboration with Novo Nordisk that makes all strengths of Ozempic and Wegovy pens available to eligible self-paying patients for $499 per month through its platform. The stock opened at $4.64 and traded between $4.48 and $5.41, with volume spiking to 49.23 million shares compared to an average of 1.50 million on the Nasdaq. GoodRx has a 52-week range of $3.31 to $8.80.
The move marks the first time Ozempic has been offered at this self-pay price and expands access to two of the nation's most in-demand GLP-1 medications for patients without adequate insurance coverage.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.